Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)

Trial Profile

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Glembatumumab vedotin (Primary) ; Capecitabine
  • Indications Advanced breast cancer; Triple negative breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms METRIC
  • Sponsors Celldex Therapeutics Inc
  • Most Recent Events

    • 02 Feb 2019 This trial has been completed in UK - MHRA, according to European Clinical Trials Database.
    • 16 Apr 2018 According to a Celldex Therapeutics media release, status changed from not yet recruiting to discontinued, because based on the data from METRIC study, company has decided to discontinue the glembatumumab vedotin program across all indications.
    • 16 Apr 2018 Results published in a Celldex Therapeutics Media Release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top